Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-11-06

Clinical Trial Update: Evaluate Severe Hepatic Impairment on Dacomitinib PK [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the pharmacokinetics of dacomitinib in patients with severe hepatic impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dacomitinib (dacomitinib)

Snippet

Sponsor: Pfizer | Conditions: Severe Hepatic Impairment | Phase 1 | Status: COMPLETED | Results posted: 2020-11-06